An interventional study of Oral metoclopramide and ibuprofen and Intravenous metoclopramide and ketorolac in Acute Migraine Headache, sponsored by Health Sciences North Research Institute. Withdrawn. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Health Sciences North Research Institute · Not applicable, Interventional, and Treatment
The project proved not feasible to launch at Health Sciences North.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing metoclopramide in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Metoclopramide · Migraine Disorders.
Among the 10 studies testing metoclopramide in Migraine Disorders, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 2 with no phase, and was the 10th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →None of the 10 studies testing metoclopramide in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →
Metoclopramide: first FDA approval 1979 (REGLAN). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 100 across the 10 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
Health Sciences North Research Institute is the lead sponsor of 10 studies on the registry; none are open to participants now.
Health Sciences North Research Institute has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing metoclopramide in Migraine Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot randomized control trial is to assess the feasibility of our patient recruitment and data collection strategy ahead of a full scale RCT investigating the efficacy of oral v. parenteral medications in the management of acute migraine headaches in the emergency department. Patients will be randomly assigned to receive either (A) standard medical therapy for the treatment of acute migraine headache (metoclopramide and ketorolac IV) and oral placebo or (B) oral metoclopramide and ibuprofen with normal saline IV. Primary outcome measures are recruitment rate and improvement in pain score at 60 minutes from medication administration.
Objectives
The planned study is a pilot study designed to assess the feasibility of our recruitment and data collection strategy. The primary feasibility outcome will be recruitment rate, which is defined as the proportion of eligible patients approached who are successfully recruited over the proposed 6-month pilot study period. Our secondary feasibility outcomes are (a) proportion of eligible patients approached and (b) rate of attrition during the study period.
Our preliminary primary outcome will be improvement in pain from baseline to 60 minutes after medication administration using the visual analogue scale (Bijur et al. 2008). Preliminary secondary outcomes will include headache relief and freedom from headache at 2 h, the need for rescue medication, ED length of stay and return to ED within 24h of discharge. The frequency of adverse effects, including gastrointestinal upset, patient-reported restlessness or dystonic reaction and fatigue, will be assessed.
Design
In this parallel, noninferiority, double-blind randomised control pilot study, eligible patients presenting to the emergency department with a chief complaint of headache will be randomly assigned with an allocation ratio of 1:1 to receive one of 2 treatments: intravenous ketorolac (10 mg) and metoclopramide (10 mg) v. oral ibuprofen (400 mg) and metoclopramide (10 mg). Dosing was selected to reflect the lowest effective doses recommended for emergency department management of migraine headaches (Friedman et al. 2011, Motov et al. 2017). The study will last 6 months at which time it will stop.
Study population
Patients between the ages of 18 and 64 presenting to the ED with a chief complaint of headache will be eligible to participate in the study. Exclusion criteria include vomiting or inability to tolerate oral medications at the time of medication administration, focal neurologic symptoms, head trauma within 14 days, history of renal disease, contraindication to NSAIDs including pregnancy or concurrent use of blood thinners, hypersensitivity reaction to any of the study medications, or >15 headache days per month.
Study procedures
Treatment will be assigned using a random number generator. Contents of treatment, which will be identical in appearance, will be known only to the research pharmacist and this information will be stored remotely from the ED. Administering nurses and treating physicians will be blind to the treatment group, as will patients and research assistants collecting outcome data.
Data collection
Data will be collected using patient interviews immediately prior to medication administration and repeated at 1 and 2 hours after medication administration. A chart review will then be conducted to check for return visits within 24 h of ED discharge.
Enrolment:
Based on sample size calculations, 55 patients will be enrolled.
Statistical procedures:
Primary and secondary feasibility outcomes will be reported as the proportion of patients approached who were recruited, proportion of eligible patients approached and the proportion who withdrew consent during the study period +/- 95% CI.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →Health Sciences North Research Institute is the lead sponsor of 10 studies on the registry; none are open to participants now.
Compared within Migraine Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Emergencies. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Presentation to emergency department with headache
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml NS administered over 15 minutes.
Drug: Oral metoclopramide and ibuprofen
2 x placebo tablets, 10 mg metoclopramide in 50 cc NS and 10 mg ketorolac in 50 ml NS administered over 15 min.
Drug: Intravenous metoclopramide and ketorolac
Drug pages: MetoclopramideStudies of MetoclopramideMetoclopramide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.
Also known as: Maxeran, Reglan
Drug pages: MetoclopramideStudies of MetoclopramideMetoclopramide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · KetorolacStudies of KetorolacKetorolac pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
Also known as: Maxeran, Reglan, Toradol
Recruitment rate
Proportion of eligible patients presenting to ED who are successfully recruited
Time frame: 6 months
Pain relief
Change in visual analogue scale (0-10 where 0 is no pain and 10 is maximal pain) from baseline to 60 minutes after medication administration
Time frame: 60 minutes
Proportion of eligible patients approached
Proportion of all eligible patients who were approached by research assistants
Time frame: 6 months
Rate of attrition during the study period
Number of patients recruited to study who ended participation during study period
Time frame: 24 hours
Pain relief at 2 hours
Change in visual analogue scale from baseline to 120 minutes after medication administration
Time frame: 120 minutes
Freedom from headache
Patients who report complete resolution of headache at 60 minutes from medication administration
Time frame: 60 minutes
Need for rescue medication
Additional medications administered by treating physician after 60 minutes
Time frame: 24 h
Emergency department length of stay
Time from initial physician assessment to discharge
Time frame: 24 hours
Return to emergency department
Patients who were registered again to the ED within 24 hours of discharge
Time frame: 24 hours
Adverse reactions
Any adverse reaction reported during the study period
Time frame: 24 hours
No study locations are listed for this record.
Plan to share: No
Ran from Jun 2023 to primary completion in Aug 2026, 37 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Jan 2024 → Jun 2023, primary completion Jun 2024 → Aug 2026 and completion Jun 2024 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The project proved not feasible to launch at Health Sciences North.
The project proved not feasible to launch at Health Sciences North.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metoclopramide · Ibuprofen
Health Sciences North Research Institute